NasdaqGS:IONSBiotechs
3 US Drug Stocks With Domestic Manufacturing And Trade Risk Exposure
Germany’s tougher stance on drug pricing and the new U.S. Section 301 investigation into those policies have turned the spotlight onto where medicines are actually made and how exposed each stock might be to trade friction. For U.S. investors, this creates a fresh filter for thinking about domestic pharmaceutical manufacturers that could be helped or hurt as global pricing and tariff risks evolve. This article walks through three U.S. drug manufacturing stocks that appear positioned on the...